Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on August 12, 2021. The filing serves to announce financial results for the quarter ended June 30, 2021, and to disclose an updated corporate presentation. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol OCUP.
Key Financial Metrics
The provided text is a cover report and does not contain specific financial data points. It references a press release (Exhibit 99.1) for the actual results. Consequently, the following metrics are not provided in this filing text:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not detail specific material changes in financial performance or operations compared to prior periods. It only confirms the issuance of a press release containing the Q2 2021 results.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers. It notes that the press release and corporate presentation contain forward-looking statements based on current expectations, which are not guarantees of future performance. Actual results may differ materially due to risks and uncertainties. No specific guidance or outlook figures are included in this text.
Investor Verification Checklist
- Verify the correct company name: The filing is for Ocuphire Pharma, Inc., not Opus Genetics, Inc.
- Review Exhibit 99.1 (Press Release) for actual Q2 2021 revenue, net loss, and cash position figures.
- Review Exhibit 99.2 (Corporate Presentation) for updated strategic outlook and operational milestones.
- Confirm the trading symbol OCUP on the Nasdaq Capital Market.